Medipharm Labs (TSE:LABS) had its price target cut by Pi Financial from C$1.75 to C$1.25 in a research note released on Monday, BayStreet.CA reports. They currently have a neutral rating on the stock.
LABS has been the subject of a number of other research reports. ATB Capital dropped their price target on Medipharm Labs from C$2.15 to C$2.00 in a research note on Monday. AltaCorp Capital lowered shares of Medipharm Labs from an outperform rating to a sector perform rating and decreased their price objective for the stock from C$4.30 to C$2.15 in a report on Friday, June 19th. Finally, Canaccord Genuity reaffirmed a speculative buy rating and set a C$2.25 target price on shares of Medipharm Labs in a research note on Monday, July 6th.
Shares of LABS stock opened at C$0.95 on Monday. The company has a market cap of $138.77 million and a price-to-earnings ratio of -6.38. Medipharm Labs has a fifty-two week low of C$0.83 and a fifty-two week high of C$5.63. The stock has a 50 day simple moving average of C$1.09. The company has a current ratio of 3.20, a quick ratio of 1.64 and a debt-to-equity ratio of 13.90.
About Medipharm Labs
MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia. It also provides cannabis contract processing services to licensed producers and growers; and tolling services to licensed cultivators in Canada.
Recommended Story: Terms to Better Understand Call Options
Receive News & Ratings for Medipharm Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medipharm Labs and related companies with MarketBeat.com's FREE daily email newsletter.